ABIO
Price:
$28.8
Market Cap:
$34.82M
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. Its lead product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), which is in Phase IIb clinical trial for the treatment for COVID-19; and Gencaro (bucindolol hydrochloride), a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial; and research collaboration with Colorad...[Read more]
Industry
Biotechnology
IPO Date
1997-08-08
Stock Exchange
NASDAQ
Ticker
ABIO
According to ARCA biopharma, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -4.90. This represents a change of -91.43% compared to the average of -57.15 of the last 4 quarters.
The mean historical PE Ratio of ARCA biopharma, Inc. over the last ten years is -24.76. The current -4.90 PE Ratio has changed 1.88% with respect to the historical average. Over the past ten years (40 quarters), ABIO's PE Ratio was at its highest in in the March 2018 quarter at -7.47. The PE Ratio was at its lowest in in the December 2022 quarter at -128.07.
Average
-24.76
Median
-21.06
Minimum
-55.08
Maximum
-6.99
Discovering the peaks and valleys of ARCA biopharma, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 137.37%
Maximum Annual PE Ratio = -6.99
Minimum Annual Increase = -51.48%
Minimum Annual PE Ratio = -55.08
Year | PE Ratio | Change |
---|---|---|
2023 | -55.08 | 24.40% |
2022 | -44.28 | 137.37% |
2021 | -18.65 | -19.86% |
2020 | -23.28 | 40.92% |
2019 | -16.52 | 136.33% |
2018 | -6.99 | -23.53% |
2017 | -9.14 | -51.48% |
2016 | -18.84 | -38.57% |
2015 | -30.66 | 26.64% |
2014 | -24.21 | -3.42% |
The current PE Ratio of ARCA biopharma, Inc. (ABIO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-39.34
5-year avg
-31.56
10-year avg
-24.76
ARCA biopharma, Inc.’s PE Ratio is less than Aerovate Therapeutics, Inc. (-0.62), less than Adagene Inc. (-2.86), less than Acrivon Therapeutics, Inc. Common Stock (-4.23), less than Rezolute, Inc. (-3.80), less than AN2 Therapeutics, Inc. (-0.47), less than Indaptus Therapeutics, Inc. (-0.78), less than Tempest Therapeutics, Inc. (-0.88), less than Comera Life Sciences Holdings, Inc. (-0.01), less than Forte Biosciences, Inc. (-0.39), less than ZIVO Bioscience, Inc. (-2.46), less than RenovoRx, Inc. (-3.02), less than Pasithea Therapeutics Corp. (-0.27), less than Quoin Pharmaceuticals, Ltd. (-0.47), less than Sio Gene Therapies Inc. (-4.77), less than Magenta Therapeutics, Inc. (-0.04), less than TRACON Pharmaceuticals, Inc. (0), less than CytomX Therapeutics, Inc. (0.03), less than Spero Therapeutics, Inc. (9.19), less than Neoleukin Therapeutics, Inc. (4.06), less than Instil Bio, Inc. (-0.98), less than NextCure, Inc. (-0.78), less than null (-0.65),
Company | PE Ratio | Market cap |
---|---|---|
-0.62 | $54.85M | |
-2.86 | $115.55M | |
-4.23 | $250.26M | |
-3.80 | $240.80M | |
-0.47 | $30.44M | |
-0.78 | $14.58M | |
-0.88 | $31.26M | |
-0.01 | $682.38K | |
-0.39 | $11.11M | |
-2.46 | $37.03M | |
-3.02 | $24.47M | |
-0.27 | $4.37M | |
-0.47 | $3.06M | |
-4.77 | $30.70M | |
-0.04 | $42.44M | |
0 | $194.57K | |
0.03 | $93.74M | |
9.19 | $71.07M | |
4.06 | $8.20M | |
-0.98 | $92.68M | |
-0.78 | $39.73M | |
-0.65 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ARCA biopharma, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ARCA biopharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is ARCA biopharma, Inc.'s PE Ratio?
How is the PE Ratio calculated for ARCA biopharma, Inc. (ABIO)?
What is the highest PE Ratio for ARCA biopharma, Inc. (ABIO)?
What is the 3-year average PE Ratio for ARCA biopharma, Inc. (ABIO)?
What is the 5-year average PE Ratio for ARCA biopharma, Inc. (ABIO)?
How does the current PE Ratio for ARCA biopharma, Inc. (ABIO) compare to its historical average?